Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
(2021) Annals of Oncology — Vol. 32, n° 6, p. 810-811 (2021)
Files
2021_Thomas_Ann_Oncol.pdf
Open Access - Adobe PDF
- 166.21 KB
Details
- Authors
- Abstract
- Each year in France, >75 000 patients receive fluoropyrimidines, including 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Xeloda), to treat digestive, breast and head and neck cancers.1 Among them, ∼20% will experience severe hematological and digestive toxicities and <2% will have a fatal outcome in the first two cycles. A part of these toxicities may result from a deficiency in dihydropyrimidine dehydrogenase (DPD) which catabolizes the endogenous uracil (U) into dihydrouracil (UH2) as well as 5-FU. In 2018, French Health Authorities [Haute Autorité de Santé (HAS) and Institut National du Cancer, (INCa)] recommended the evaluation of the enzymatic activity of DPD by measuring the plasma U concentration before administration of fluoropyrimidines. [...]
- Affiliations
Citations
Thomas, F., Maillard, M., Launay, M., Tron, C., Etienne-Grimaldi, M.-C., Gautier-Veyret, E., Haufroid, V., Pallet, N., Royer, B., Narjoz, C., & Schmitt, A. (2021). Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Annals of Oncology, 32(6), 810-811. https://doi.org/10.1016/j.annonc.2021.02.020 (Original work published 2021)